| 程 蒙,姜 达,李 颖.乳腺癌辅助治疗中应用双膦酸盐的回顾性分析[J].肿瘤学杂志,2015,21(9):762-767. |
| 乳腺癌辅助治疗中应用双膦酸盐的回顾性分析 |
| A Retrospective Analysis of Adjuvant Therapy with Bisphosphonates for Breast Cancer |
| 投稿时间：2014-06-12 |
| DOI：10.11735/j.issn.1671-170X.2015.09.B013 |
|
 |
| 中文关键词: 双膦酸盐 辅助治疗 乳腺肿瘤 无病生存时间 骨密度 |
| 英文关键词:bisphosphonates adjuvant therapy breast cancer disease-free survival bone mineral density |
| 基金项目: |
|
| 摘要点击次数: 2296 |
| 全文下载次数: 725 |
| 中文摘要: |
| 摘 要：［目的］ 探讨双膦酸盐(bisphosphonates，BPs)在乳腺癌辅助治疗中的意义。［方法］ 收集接受标准辅助治疗的Ⅰ~Ⅲ期乳腺癌患者的病例资料，回顾性分析BPs对患者的无病生存时间(disease-free survival，DFS)、骨质疏松/骨量减少的发生的影响。［结果］ 301例Ⅰ~Ⅲ期乳腺癌病例中，57例接受BPs治疗，BPs组DFS较对照组延长，差异具有统计学意义(P=0.037)。多因素分析发现辅助治疗联合应用BPs(HR=2.198，P=0.071)、淋巴结转移数目少(HR=1.847，P=0.000)及激素受体阳性(HR=1.522，P=0.001)是改善DFS的独立因素。分层分析结果显示，绝经后(P=0.033)、60岁以内(P=0.023)的患者是BPs辅助治疗的最佳获益人群。301例患者中52例进行骨密度(bone mineral density，BMD)检测，其中BPs组23例，对照组29例，两组骨质疏松/骨量减少的发生情况存在统计学差异(P=0.003)。Logistic回归结果显示应用BPs与否(OR=0.239)及年龄(OR=1.081)是影响骨质疏松/骨量减少发生的主要因素(P＜0.05)。［结论］ 辅助治疗联合BPs治疗可改善绝经后乳腺癌患者的预后并可有效预防BMD降低。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the significance of adjuvant therapy with bisphosphonates(BPs) for breast cancer.［Methods］ The data of breast cancer patients stage Ⅰ～Ⅲ who received standard adjuvant treatment were collected，and the impact of BPs on disease-free survival(DFS) and on the occurrence of osteoporosis/osteopenia were analyzed retrospectively. ［Results］ Of the 301 patients with breast cancer stage Ⅰ～Ⅲ，57 cases received BPs therapy. The DFS of BPs group was longer than that of control group，with significant difference between the two groups (P=0.037)。 Multivariate analysis showed that the independent factors on improving DFS included BPs adjuvant therapy(HR=2.198，P=0.071)，less number of positive axillary lymph nodes(HR=1.847，P=0.000) and positive expressions of hormone receptors(HR=1.522，P=0.001). Stratified analysis showed that patients with postmenopausal(P=0.033) and under 60 years old (P=0.023) benefited most from BPs adjuvant therapy. A total of 52 breast cancer cases had bone mineral density(BMD) examination，among them，23 patients received BPs therapy，29 patients did not. The rates of osteoporosis/osteopenia were significantly different (P=0.003) between the two groups. Logistic regression showed that BPs adjuvant therapy(OR=0.239) and age (OR=1.081) were important factors influencing the occurrence of osteoporosis/osteopenia(P＜0.05). ［Conclusion］ Adjuvant therapy with BPs might improve prognosis in postmenopausal patients with breast cancer and prevent loss of BMD. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |